51186 Patient-reported well-being using tildrakizumab in a real-world setting: 28-week interim data of the phase IV POSITIVE study - 01/09/24
Doi : 10.1016/j.jaad.2024.07.1100
Ulrich Mrowietz, Psoriasis-Center
Department of Dermatology, University Medical Center Schleswig-Holstein
Campus Kiel
Rachel Sommer, Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
Esteban Daudén
La Princesa University Hospital, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Spain
Julia-Tatjana Maul
Department of Dermatology, University Hospital Zurich, and Faculty of Medicine, University of Zurich, Zurich, Switzerland
Matthias Augustin
Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
Le texte complet de cet article est disponible en PDF.
| Commercial Support: This work was supported by Almirall, Barcelona, Spain. |
© 2024
Publié par Elsevier Masson SAS.
Vol 91 - N° 3S
P. AB277 - septembre 2024 Retour au numéro
Article précédent
- 53817 Patient-reported outcomes with roflumilast foam 0.3% in patients with scalp and body psoriasis in the phase 3 ARRECTOR trial
- Melinda Gooderham, Jerry Bagel, Seth B. Forman, Leon Kircik, Marni Wiseman, Benjamin Lockshin, Jennifer Soung, David Krupa, Saori Kato, David R. Berk, David H. Chu
- 51620 Patterns in the risk factors, triggers, and management of chronic hand eczema in pediatric and adolescent populations: A systematic review
- Katie Yeung, Joshua Lowe, Jessica Ho, Sonja Molin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?